Shantel Holcomb/LinkedIn
Nov 7, 2025, 03:28
Shantel Holcomb: Boston Scientific is Investing in Innovative Solutions to Improve Outcomes for Patients With CAD
Shantel Holcomb, Senior Talent Acquisition Specialist at Boston Scientific, posted on LinkedIn:
“Did you know that coronary artery disease (CAD) is the leading cause of death worldwide? Boston Scientific is investing in innovative solutions to improve outcomes for patients with CAD.”
Read full paper here.
Stay informed with Hemostasis Today.
-
Jun 4, 2026, 13:31Fredrick Chalinga: Microcytic Anemia Does Not Always Mean Iron Deficiency
-
Jun 4, 2026, 13:23How Access to Care Changed One Life – WFH
-
Jun 4, 2026, 13:16Muhammad Usman Arshad: Meta-Analysis Supports Expanding Role of DOACs in Cancer-Associated Thromboembolism
-
Jun 4, 2026, 12:59Dual Prognostic Significance of P2RY12 in Antithrombotic-Treated STEMI – JTH
-
Jun 4, 2026, 12:43Beth Wallace: Raising Awareness of Hereditary Haemochromatosis
-
Jun 4, 2026, 11:57José María Bastida Bermejo: IPDs Help to Better Understand Platelet Biogenesis and Function
-
Jun 4, 2026, 11:07Cristina Pecorilla: PSG6 and A New Approach to Cancer-Associated Thrombosis
-
Jun 4, 2026, 10:55Jacqui McCallum: Stroke Foundation Brings Stroke Advocacy to State Parliaments
-
Jun 4, 2026, 10:47Eugene Tang: Do Dementia-Predicting Scores Work for Stroke Patients?